Clinical Trials Regulatory Affairs Regulatory Approval Clinical Research Therapeutics Oncology Pharmaceutical Research FDA Approval Weight-loss Drugs RNA-based Therapeutics Mifepristone Ruling Stelara Loss of Exclusivity Disease Treatment Pharmaceuticals Experimental Treatments GLP-1 Drugs Injectable Medications Biotechnology Gene Therapy Research Applications Therapeutic Segments Tyrosine Kinase Inhibitors Phase 3 Trials Innovative Therapies Combination Therapy Therapeutic Targets Efficacy Studies Drug Testing Subcutaneous Administration Intellectual Property Alzheimer's Disease Alzheimer's Scientific Research Biologics Preclinical Research FDA Regulations Therapeutic Research Research Studies
The 31‑patient BEACON trial met key efficacy measures with no serious adverse events, positioning the oral TYK2/JAK1 inhibitor for a Phase 3 start in 2026 pending FDA input.
